- Home
- UROY vs LAB Comparison
UROY vs LAB Comparison
Compare UROY & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- LAB
- Stock Information
- Founded
- UROY 2017
- LAB 1999
- Country
- UROY Canada
- LAB United States
- Employees
- UROY N/A
- LAB N/A
- Industry
- UROY
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- UROY
- LAB Industrials
- Exchange
- UROY Nasdaq
- LAB Nasdaq
- Market Cap
- UROY 336.8M
- LAB 372.1M
- IPO Year
- UROY N/A
- LAB 2011
- Fundamental
- Price
- UROY $2.48
- LAB $1.35
- Analyst Decision
- UROY Strong Buy
- LAB Buy
- Analyst Count
- UROY 2
- LAB 2
- Target Price
- UROY $4.00
- LAB $2.50
- AVG Volume (30 Days)
- UROY 4.0M
- LAB 2.6M
- Earning Date
- UROY 07-23-2025
- LAB 07-30-2025
- Dividend Yield
- UROY N/A
- LAB N/A
- EPS Growth
- UROY N/A
- LAB N/A
- EPS
- UROY N/A
- LAB N/A
- Revenue
- UROY $15,984,827.00
- LAB $169,687,000.00
- Revenue This Year
- UROY N/A
- LAB N/A
- Revenue Next Year
- UROY N/A
- LAB $12.18
- P/E Ratio
- UROY N/A
- LAB N/A
- Revenue Growth
- UROY N/A
- LAB 33.86
- 52 Week Low
- UROY $1.43
- LAB $0.92
- 52 Week High
- UROY $3.12
- LAB $2.41
- Technical
- Relative Strength Index (RSI)
- UROY 57.92
- LAB 64.54
- Support Level
- UROY $2.38
- LAB $1.15
- Resistance Level
- UROY $2.54
- LAB $1.31
- Average True Range (ATR)
- UROY 0.12
- LAB 0.11
- MACD
- UROY -0.01
- LAB 0.03
- Stochastic Oscillator
- UROY 69.68
- LAB 57.89
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.